TMDX — The logistics margin test
TransMedics is selling more than a device: the logistics around an organ transplant are becoming a larger part of its business.
On November 5, $TMDX reported third-quarter revenue of $203 million, up 41% year over year. Product revenue rose 29%, while service revenue rose 60%. Revenue growth included a contribution from PAD Aviation following a strategic investment; organic revenue growth was 35%.
The mix matters. On the earnings call, management said services carry a lower gross margin than products and that PAD's contribution diluted the overall gross margin. At the same time, it described improved service margins from logistics efficiencies. More revenue from moving organs can therefore change the company's margin even as individual operations become more efficient.
The company raised its 2026 revenue outlook to $750 million–$760 million excluding PAD, and $764 million–$774 million including it. Those ranges should not be compared as though they cover the same business.
The next report can test whether the expanded logistics operation supports both growth and profitability. Compare organic service growth, service margins and the PAD contribution, then check whether operating expenses are growing more slowly than revenue.